Digest Network Come funziona
Network
/
Società
Fe
Non verificato

Ferrer

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

9 comunicati stampa

Guarda tutti i comunicati
21/10/2025
Ferrer Completes Recruitment of 220 Patients for the PROSPER Study, a Phase II Clinical Trial in Progressive Supranuclear Palsy (PSP), Two Months Ahead of Schedule
Fonte
Ferrer
Emittente
Business Wire
1.00
0
17/06/2025
Ferrer Receives FDA Fast Track Designation for FNP-223 in Progressive Supranuclear Palsy (PSP)
Fonte
Ferrer
Emittente
Business Wire
1.00
0
03/06/2025
A Hundred Experts Urge Strengthening Early Diagnosis of Pulmonary Hypertension in Latin America
Fonte
Ferrer
Emittente
Business Wire
1.00
0
28/04/2025
Mercato del lavoro
Biotecnologia
Farmaceutica
Salute
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine
Fonte
Ferrer
Emittente
Business Wire
1.00
0
31/03/2025
Experts Set International and Multidisciplinary Collaboration As Priorities in Pulmonary Hypertension Management
Fonte
Ferrer
Emittente
Business Wire
1.00
0
20/02/2025
Multimedialità
Responsabilità sociale d'impresa
Industria
Farmaceutica
Associazioni/Professionisti
Ecologia/Salute ambientale
Trasporto e spedizione merci
Biotecnologia
Logistica
Salute
Ferrer is the Highest-performing Pharmaceutical Company in the World for Social and Environmental Impact According to B Corp
Fonte
Ferrer
Emittente
Business Wire
1.00
0
30/01/2025
Ferrer is Recognized for Its Best-in-class Ethics and Compliance Program
Fonte
Ferrer
Emittente
Business Wire
1.00
0
20/11/2024
Analisi di mercato
Industria
Scienza
Medicina - Varie
Cardiologia
Management
Biotecnologia
Sanità
Farmaceutica
Salute
Pulmonary Hypertension Awareness Month: Two European Studies Highlight the Urgency of Patients and Experts to Improve the Diagnosis and Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease
Fonte
Ferrer
Emittente
Business Wire
1.00
0
17/09/2024
Multimedialità
Industria
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Ferrer Advances Research into Progressive Supranuclear Palsy (PSP) with the Inclusion of the First Participant in a Phase II Clinical Trial
Fonte
Ferrer
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0